Novartis unveils new strategy based on eight multi-billion dollar brands

FAN Editor

ZURICH (Reuters) – Novartis unveiled a new strategy on Thursday based on eight drug brands which it said could generate sales in the range of multiple billions of dollars.

Ahead of an investor event, the Swiss company said the currently in-market brands – Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix – each hold multi-billion dollar peak sales potential.

Novartis also said it would focus in future on five areas for investment: cardiovascular, immunology, neuroscience, solid tumors and hematology medicine – and had “multiple significant in-market and pipeline assets in each of these areas.”

(Reporting by John Revill, editing by Rachel More)


Free America Network Articles

Leave a Reply

Next Post

Xpeng breaks out of a lower price range with its most expensive car to date

Xpeng has announced its most expensive car to date. Pictured here at a store in Shanghai, China, on July 2021 are two of Xpeng’s previously released models, a P7 Wing Limited Edition in green and a G3 SUV in blue. Qilai Shen | Bloomberg | Getty Images BEIJING — Chinese […]